3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 154,663 | 357,200 |
受取手形及び売掛金 | 233,472 | 137,865 |
商品及び製品 | 751,925 | 674,560 |
仕掛品 | 22,137 | - |
原材料及び貯蔵品 | 57,355 | 56,999 |
預け金 | 179,083 | - |
未収入金 | 587 | 244,225 |
前払金 | 104,417 | 141,294 |
短期貸付金 | - | 133,000 |
暗号資産 | - | 154,154 |
その他 | 39,596 | 69,475 |
貸倒引当金 | △2,980 | △133,955 |
流動資産合計 | 1,540,257 | 1,834,820 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 278,833 | 32,338 |
減価償却累計額 | △96,011 | △30,802 |
建物及び構築物(純額) | 182,821 | 1,536 |
機械装置及び運搬具 | 260,130 | 29,852 |
減価償却累計額 | △130,241 | △27,536 |
機械装置及び運搬具(純額) | 129,888 | 2,315 |
工具、器具及び備品 | 213,551 | 192,784 |
減価償却累計額 | △176,473 | △186,053 |
工具、器具及び備品(純額) | 37,078 | 6,731 |
土地 | 551,097 | 499,999 |
建設仮勘定 | 524,032 | - |
有形固定資産合計 | 1,424,918 | 510,582 |
無形固定資産 | | |
のれん | 241,056 | - |
ソフトウエア | 6,209 | 4,664 |
その他 | 161 | 89 |
無形固定資産合計 | 247,428 | 4,753 |
投資その他の資産 | | |
関係会社株式 | - | 138,521 |
長期未収入金 | 132,741 | 141,939 |
敷金及び保証金 | 36,499 | 37,899 |
その他 | 16,334 | 330 |
貸倒引当金 | △145,891 | △141,939 |
投資その他の資産合計 | 39,684 | 176,752 |
固定資産合計 | 1,712,030 | 692,089 |
資産合計 | 3,252,288 | 2,526,909 |
| | (単位:千円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | 182,128 | 146,937 |
短期借入金 | 95,000 | 250,000 |
1年内返済予定の長期借入金 | 41,786 | - |
未払金 | 118,451 | 138,932 |
未払法人税等 | 6,958 | 8,071 |
契約負債 | 5,880 | 6,604 |
賞与引当金 | 17,180 | 17,065 |
資産除去債務 | 16,348 | - |
その他 | 74,095 | 42,603 |
流動負債合計 | 557,829 | 610,214 |
固定負債 | | |
長期借入金 | 156,606 | - |
繰延税金負債 | 12,823 | - |
資産除去債務 | 10,389 | 10,573 |
その他 | 39,762 | 300 |
固定負債合計 | 219,581 | 10,873 |
負債合計 | 777,410 | 621,088 |
純資産の部 | | |
株主資本 | | |
資本金 | 1,851,763 | 2,214,855 |
資本剰余金 | 2,912,688 | 3,275,780 |
利益剰余金 | △2,308,176 | △3,584,814 |
株主資本合計 | 2,456,275 | 1,905,821 |
新株予約権 | 18,601 | - |
純資産合計 | 2,474,877 | 1,905,821 |
負債純資産合計 | 3,252,288 | 2,526,909 |
E0567438400パス株式会社PATH corporation通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-04-012026-03-31FY2026-03-312024-04-012025-03-312025-03-311falsefalsefalse384002024-04-012025-03-31tse-acedjpfr-38400:CosmeticsBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:BeautyAndWellnessBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:MarketExpansionBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:InvestmentBusinessReportableSegmentsMember384002025-04-012026-03-31tse-acedjpfr-38400:AITechnologyReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:AITechnologyReportableSegmentsMember384002026-03-31jppfs_cor:ShareholdersEquityMember384002026-03-31jppfs_cor:CapitalStockMember384002026-03-31jppfs_cor:CapitalSurplusMember384002026-03-31jppfs_cor:RetainedEarningsMember384002026-03-31jppfs_cor:SubscriptionRightsToSharesMember384002025-04-012026-03-31jppfs_cor:CapitalStockMember384002025-04-012026-03-31jppfs_cor:CapitalSurplusMember384002025-04-012026-03-31jppfs_cor:RetainedEarningsMember384002025-04-012026-03-31jppfs_cor:SubscriptionRightsToSharesMember384002024-04-012025-03-31jppfs_cor:CapitalStockMember384002024-04-012025-03-31jppfs_cor:CapitalSurplusMember384002026-05-13384002026-03-31384002025-04-012026-03-31384002025-03-31384002024-04-012025-03-31384002024-03-31384002025-04-012026-03-31jpcrp_cor:ReportableSegmentsMember384002024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember384002025-04-012026-03-31tse-acedjpfr-38400:RegenerativeMedicineRelatedBusinessReportableSegmentsMember384002025-04-012026-03-31tse-acedjpfr-38400:SustainableBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:RegenerativeMedicineRelatedBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:SustainableBusinessReportableSegmentsMember384002025-04-012026-03-31jpcrp_cor:ReconcilingItemsMember384002024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember384002025-04-012026-03-31tse-acedjpfr-38400:CosmeticsBusinessReportableSegmentsMember384002025-04-012026-03-31tse-acedjpfr-38400:BeautyAndWellnessBusinessReportableSegmentsMember384002025-04-012026-03-31tse-acedjpfr-38400:MarketExpansionBusinessReportableSegmentsMember384002025-04-012026-03-31tse-acedjpfr-38400:InvestmentBusinessReportableSegmentsMember384002024-04-012025-03-31jppfs_cor:ShareholdersEquityMember384002024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember384002025-03-31jppfs_cor:CapitalStockMember384002025-03-31jppfs_cor:CapitalSurplusMember384002025-03-31jppfs_cor:RetainedEarningsMember384002025-03-31jppfs_cor:ShareholdersEquityMember384002024-03-31jppfs_cor:CapitalStockMember384002024-03-31jppfs_cor:CapitalSurplusMember384002024-03-31jppfs_cor:RetainedEarningsMember384002024-03-31jppfs_cor:ShareholdersEquityMember384002024-03-31jppfs_cor:SubscriptionRightsToSharesMember384002024-04-012025-03-31jppfs_cor:RetainedEarningsMember384002025-04-012026-03-31jppfs_cor:ShareholdersEquityMember384002025-03-31jppfs_cor:SubscriptionRightsToSharesMemberxbrli:pureiso4217:JPY